Diamyd Medical (Germany) Performance

DMN Stock  EUR 1.39  0.07  4.79%   
On a scale of 0 to 100, Diamyd Medical holds a performance score of 11. The firm shows a Beta (market volatility) of -1.02, which means a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Diamyd Medical are expected to decrease slowly. On the other hand, during market turmoil, Diamyd Medical is expected to outperform it slightly. Please check Diamyd Medical's information ratio, treynor ratio, and the relationship between the downside deviation and total risk alpha , to make a quick decision on whether Diamyd Medical's price patterns will revert.

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Diamyd Medical AB are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Diamyd Medical reported solid returns over the last few months and may actually be approaching a breakup point. ...more
1
Will Diamyd Medical AB stock beat international competition - 2025 Earnings Impact Accurate Intraday Trading Signals - Newser
12/04/2025
2
Diamyd Medical Phase III timeline accelerated - marketscreener.com
12/29/2025
3
Diamyd Medical receives Notice of Allowance for key retogatein US patent - Yahoo Finance
02/09/2026
  

Diamyd Medical Relative Risk vs. Return Landscape

If you would invest  94.00  in Diamyd Medical AB on November 30, 2025 and sell it today you would earn a total of  45.00  from holding Diamyd Medical AB or generate 47.87% return on investment over 90 days. Diamyd Medical AB is currently producing 0.7887% returns and takes up 5.5427% volatility of returns over 90 trading days. Put another way, 49% of traded stocks are less volatile than Diamyd, and 85% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon Diamyd Medical is expected to generate 7.31 times more return on investment than the market. However, the company is 7.31 times more volatile than its market benchmark. It trades about 0.14 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.08 per unit of risk.

Diamyd Medical Target Price Odds to finish over Current Price

The tendency of Diamyd Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 1.39 90 days 1.39 
about 24.2
Based on a normal probability distribution, the odds of Diamyd Medical to move above the current price in 90 days from now is about 24.2 (This Diamyd Medical AB probability density function shows the probability of Diamyd Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon Diamyd Medical AB has a beta of -1.02 suggesting Moreover Diamyd Medical AB has an alpha of 1.0533, implying that it can generate a 1.05 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Diamyd Medical Price Density   
       Price  

Predictive Modules for Diamyd Medical

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Diamyd Medical AB. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.071.396.93
Details
Intrinsic
Valuation
LowRealHigh
0.061.116.65
Details
Naive
Forecast
LowNextHigh
0.031.306.84
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.391.391.39
Details

Diamyd Medical Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Diamyd Medical is not an exception. The market had few large corrections towards the Diamyd Medical's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Diamyd Medical AB, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Diamyd Medical within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
1.05
β
Beta against Dow Jones-1.02
σ
Overall volatility
0.30
Ir
Information ratio 0.16

Diamyd Medical Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Diamyd Medical for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Diamyd Medical AB can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Diamyd Medical AB is way too risky over 90 days horizon
Diamyd Medical AB may become a speculative penny stock
Diamyd Medical AB appears to be risky and price may revert if volatility continues
Diamyd Medical AB has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 130 K. Net Loss for the year was (169.78 M) with loss before overhead, payroll, taxes, and interest of (3.71 M).
Diamyd Medical generates negative cash flow from operations
About 26.0% of the company shares are held by company insiders
Latest headline from news.google.com: Diamyd Medical receives Notice of Allowance for key retogatein US patent - Yahoo Finance

Diamyd Medical Fundamentals Growth

Diamyd Stock prices reflect investors' perceptions of the future prospects and financial health of Diamyd Medical, and Diamyd Medical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Diamyd Stock performance.

About Diamyd Medical Performance

By analyzing Diamyd Medical's fundamental ratios, stakeholders can gain valuable insights into Diamyd Medical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Diamyd Medical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Diamyd Medical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Diamyd Medical AB , a diabetes company, engages in the development of combination therapies for the treatment of autoimmune diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB in April 2013. DIAMYD MEDICAL operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 6 people.

Things to note about Diamyd Medical AB performance evaluation

Checking the ongoing alerts about Diamyd Medical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Diamyd Medical AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Diamyd Medical AB is way too risky over 90 days horizon
Diamyd Medical AB may become a speculative penny stock
Diamyd Medical AB appears to be risky and price may revert if volatility continues
Diamyd Medical AB has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 130 K. Net Loss for the year was (169.78 M) with loss before overhead, payroll, taxes, and interest of (3.71 M).
Diamyd Medical generates negative cash flow from operations
About 26.0% of the company shares are held by company insiders
Latest headline from news.google.com: Diamyd Medical receives Notice of Allowance for key retogatein US patent - Yahoo Finance
Evaluating Diamyd Medical's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Diamyd Medical's stock performance include:
  • Analyzing Diamyd Medical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Diamyd Medical's stock is overvalued or undervalued compared to its peers.
  • Examining Diamyd Medical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Diamyd Medical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Diamyd Medical's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Diamyd Medical's stock. These opinions can provide insight into Diamyd Medical's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Diamyd Medical's stock performance is not an exact science, and many factors can impact Diamyd Medical's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Diamyd Stock analysis

When running Diamyd Medical's price analysis, check to measure Diamyd Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Diamyd Medical is operating at the current time. Most of Diamyd Medical's value examination focuses on studying past and present price action to predict the probability of Diamyd Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Diamyd Medical's price. Additionally, you may evaluate how the addition of Diamyd Medical to your portfolios can decrease your overall portfolio volatility.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum